Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics
Eroom’s law (Moore’s law spelled backwards), describes adverse trends towards declining innovation and rising costs of drug development over the last several decades. Therapeutics for cardiovascular diseases (CVD) appear to have been particularly sensitive to these trends. Thirty-three percent fewer...
Main Author: | Gail A. Van Norman, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-10-01
|
Series: | JACC: Basic to Translational Science |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452302X17302231 |
Similar Items
-
Drugs approved by CDSCO, India in 2015
by: K Parushuram Naik1 , V Sai Lakshmi2 , J Jyothirmai3
Published: (2016-04-01) -
Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021
by: Alexander C. Martins, et al.
Published: (2022-09-01) -
Editorial: Adopting drug repurposing to overcome drug resistance in cancer
by: Eswar Shankar, et al.
Published: (2023-04-01) -
International oncology drug approvals for multiregional or single-country clinical trials: A systematic review
by: Min Zhang, et al.
Published: (2022-12-01) -
A review of new drugs approved by the food and drug administration in 2022
by: Arjun Swaminathan, et al.
Published: (2023-01-01)